EVERSANA® Announces Partnership with ChemoMouthpiece, LLC
The partnership was sealed to support U.S. launch & commercialization of a medical device to help cancer patients manage and treat oral mucositis.
EVERSANA, a commercialization services provider for the life science industry, has announced a partnership with ChemoMouthpiece, LLC to support the launch and commercialization of its medical device, the Chemo Mouthpiece™.
The device is an intraoral ice pack that delivers cryotherapy to the oral cavity of a patient receiving chemotherapy, to manage and treat oral mucositis, a common and painful side effect of chemotherapy. The FDA recently granted Breakthrough Device Designation to the Chemo Mouthpiece™ for reducing the incidence and severity of oral mucositis caused by chemotherapy.
Under the partnership, EVERSANA will provide a full range of commercialization services to support the launch of the device in the US, including market access strategy, compliance and regulatory services, patient services, field deployment solutions, data and analytics, pricing strategy, and 3PL distribution services. The Chemo Mouthpiece™ is expected to launch in the US in late 2023.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
